SINGULAIR'S LABEL HAS BEEN UPDATED: The following has been add...

SINGULAIR'S LABEL HAS BEEN UPDATED: The following has been added to the "Precautions" section of Singulair's label: "Neuropsychiatric Events Neuropsychiatric events have been reported in adult, adolescent, and pediatric patients taking SINGULAIR. Post-marketing reports with SINGULAIR use include agitation, aggressive behavior or hostility, anxiousness, depression, dream abnormalities, hallucinations, insomnia, irritability, restlessness, somnambulism, suicidal thinking and behavior (including suicide), and tremor. The clinical details of some post-marketing reports involving SINGULAIR appear consistent with a drug-induced effect. Patients and prescribes should be alert for neuropsychiatric events. Patients should be instructed to notify their prescribe if these changes occur. Prescribes should carefully evaluate the risks and benefits of continuing treatment with SINGULAIR if such events occur (see ADVERSE REACTIONS, Post- Marketing Experience)."